News & Policy

NYT article about a telehealth provider

Andrew Huberman Slams ‘Peptides’ Media Coverage as a “Dog’s Breakfast,” Says Pharma Divide Fuels Black and Gray Markets

New GLP-1 pill approval sparks talk on access, side effects, and daily vs weekly use

FDA has now approved Orforglipron

Retatrutide brand name ideas?

Reta Passes Another Trial

Proper refillable insulin pen

MAHA peptide push?

New higher doses of semaglutide receives FDA approval

Podcast Guest Highlights Pharma Lobbying on Peptides Despite Acquisition Deal

Weight regain after stopping GLP's

Need help with recommendations for my father in law

Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit

Can Ozempic cure Addiction?

Affordable weight loss medication production and US patent issues

FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s

Biomedind (quadruple) Even Better Answer to Novo Nordisk's Answer to Retatrutide.? NA-931

Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial

Stacking semaglutide with retatrutide or tirzepatide after appetite return or stalls

Current and future state of the regulatory environment regarding peptides

Shift in wellness views on GLP-1 medications after wider availability

Legal cases involved end users

Reactions to media coverage of peptide use and regulation fears

Forum thread on GLP-1 meds and vision loss

Traveling / Prescription

GHK-cu article

Dr. Oz Claims Cheaper GLP-1s and FDA-Approved Pill Are on the Way

Interesting new sleep medication trial

Risks of halting GLP-1 drugs and links to weight cycling

That's what I need!!